JP2014524746A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524746A5 JP2014524746A5 JP2014520383A JP2014520383A JP2014524746A5 JP 2014524746 A5 JP2014524746 A5 JP 2014524746A5 JP 2014520383 A JP2014520383 A JP 2014520383A JP 2014520383 A JP2014520383 A JP 2014520383A JP 2014524746 A5 JP2014524746 A5 JP 2014524746A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- tumor
- cancer
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 98
- 101000825949 Homo sapiens R-spondin-2 Proteins 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 28
- 102100022763 R-spondin-2 Human genes 0.000 claims description 26
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 108060000903 Beta-catenin Proteins 0.000 claims description 15
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 102000015735 Beta-catenin Human genes 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 230000011664 signaling Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000004614 tumor growth Effects 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 208000037841 lung tumor Diseases 0.000 claims description 6
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000023958 prostate neoplasm Diseases 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims description 3
- 102000047209 human Rspo2 Human genes 0.000 claims description 2
- 229940121396 wnt pathway inhibitor Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 101710174256 Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 91
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 description 22
- 102100022762 R-spondin-1 Human genes 0.000 description 19
- 230000035772 mutation Effects 0.000 description 16
- 108700001666 APC Genes Proteins 0.000 description 12
- 230000000415 inactivating effect Effects 0.000 description 12
- 102000037126 Leucine-rich repeat-containing G-protein-coupled receptors Human genes 0.000 description 8
- 108091006332 Leucine-rich repeat-containing G-protein-coupled receptors Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 description 6
- 102100022766 R-spondin-3 Human genes 0.000 description 6
- 238000010208 microarray analysis Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101000825962 Homo sapiens R-spondin-4 Proteins 0.000 description 4
- 102100022759 R-spondin-4 Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102000050526 human RSPO1 Human genes 0.000 description 3
- 101001063463 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 description 2
- 101000981765 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 6 Proteins 0.000 description 2
- 101100531974 Homo sapiens RSPO2 gene Proteins 0.000 description 2
- 102100031035 Leucine-rich repeat-containing G-protein coupled receptor 4 Human genes 0.000 description 2
- 102100024140 Leucine-rich repeat-containing G-protein coupled receptor 6 Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical group O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161508403P | 2011-07-15 | 2011-07-15 | |
| US61/508,403 | 2011-07-15 | ||
| US201161521547P | 2011-08-09 | 2011-08-09 | |
| US61/521,547 | 2011-08-09 | ||
| US201161570629P | 2011-12-14 | 2011-12-14 | |
| US61/570,629 | 2011-12-14 | ||
| PCT/US2012/046746 WO2013012747A1 (en) | 2011-07-15 | 2012-07-13 | Rspo binding agents and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017094648A Division JP2017169578A (ja) | 2011-07-15 | 2017-05-11 | Ｒｓｐｏ結合剤およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524746A JP2014524746A (ja) | 2014-09-25 |
| JP2014524746A5 true JP2014524746A5 (enExample) | 2015-09-03 |
| JP6185463B2 JP6185463B2 (ja) | 2017-08-23 |
Family
ID=47558408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520383A Expired - Fee Related JP6185463B2 (ja) | 2011-07-15 | 2012-07-13 | Ｒｓｐｏ結合剤およびその使用法 |
| JP2017094648A Ceased JP2017169578A (ja) | 2011-07-15 | 2017-05-11 | Ｒｓｐｏ結合剤およびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017094648A Ceased JP2017169578A (ja) | 2011-07-15 | 2017-05-11 | Ｒｓｐｏ結合剤およびその使用法 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8802097B2 (enExample) |
| EP (2) | EP2731625B1 (enExample) |
| JP (2) | JP6185463B2 (enExample) |
| KR (1) | KR20140048276A (enExample) |
| CN (2) | CN104023746B (enExample) |
| AU (1) | AU2012284254B2 (enExample) |
| BR (1) | BR112014000765A2 (enExample) |
| CA (1) | CA2841745A1 (enExample) |
| CL (1) | CL2014000114A1 (enExample) |
| IL (1) | IL230429A0 (enExample) |
| MX (1) | MX349198B (enExample) |
| RU (1) | RU2014101669A (enExample) |
| WO (1) | WO2013012747A1 (enExample) |
| ZA (1) | ZA201400525B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE466106T1 (de) * | 2003-10-10 | 2010-05-15 | Deutsches Krebsforsch | Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen |
| HRP20160082T1 (hr) | 2006-09-29 | 2016-02-26 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka |
| HUE027179T2 (en) | 2006-10-20 | 2016-10-28 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Angiogenesis and vasculogenesis modulator for Rspond |
| ES2694018T3 (es) | 2007-07-02 | 2018-12-17 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para el tratamiento y el diagnóstico del cáncer |
| CN102686720B (zh) * | 2009-11-17 | 2013-12-04 | 国立大学法人冈山大学 | 由牙髓细胞向成牙本质细胞的分化诱导方法 |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| WO2013012747A1 (en) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| CN104854132A (zh) | 2012-07-13 | 2015-08-19 | 昂考梅德药品有限公司 | Rspo3结合剂及其用途 |
| WO2014159764A1 (en) * | 2013-03-14 | 2014-10-02 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
| US20150147333A1 (en) * | 2013-10-18 | 2015-05-28 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
| CN103724415B (zh) * | 2013-12-31 | 2015-05-27 | 中山大学 | 斜带石斑鱼性别调控基因Rspo1及其制备方法和应用 |
| EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
| CA2958144A1 (en) * | 2014-08-15 | 2016-02-18 | Oncomed Pharmaceuticals, Inc. | Rspo1 binding agents and uses thereof |
| WO2016044295A1 (en) * | 2014-09-16 | 2016-03-24 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| MA41123A (fr) * | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| WO2017040660A1 (en) * | 2015-08-31 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| WO2017070567A1 (en) * | 2015-10-21 | 2017-04-27 | The Research Foundation For The State University Of New York | Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections |
| JP7296728B2 (ja) * | 2015-10-23 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 癌の成長を抑制する結合分子 |
| CN106913880B (zh) * | 2015-12-24 | 2021-02-12 | 上海交通大学 | 一种含有rspo1的靶向给药系统及其制备与应用 |
| RU2756275C2 (ru) | 2016-03-01 | 2021-09-29 | Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. | Антитела, специфические к рецептору полиовируса (pvr) человека |
| CN105925576B (zh) * | 2016-03-24 | 2018-04-20 | 嘉兴市第一医院 | 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用 |
| EP3443004A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Anti-rspo3 antibodies and methods of use |
| WO2017189963A1 (en) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| RS66708B9 (sr) | 2017-08-09 | 2025-08-29 | Merus Nv | Antitela koja se vezuju za egfr i cmet |
| JP7795860B2 (ja) | 2017-09-07 | 2026-01-08 | オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド | プログラム細胞死タンパク質１に対する抗体 |
| CN109529040B (zh) * | 2017-09-21 | 2020-11-13 | 华东师范大学 | LGR4和R-spondin结合抑制剂及其在肿瘤治疗中的用途 |
| KR102762570B1 (ko) | 2017-12-07 | 2025-02-06 | 내셔날 헬스 리서치 인스티튜트 | 항-rspo3 항체 |
| CN110339364B (zh) * | 2018-04-02 | 2021-02-12 | 上海邦耀生物科技有限公司 | Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗 |
| MX2020010094A (es) | 2018-04-06 | 2021-01-15 | Dana Farber Cancer Inst Inc | Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos. |
| US12497464B1 (en) | 2018-08-03 | 2025-12-16 | Berkeley Therapeutics, Inc. | Antibody, antibody fragments or peptide for treating cancer and methods of formation and administration |
| GB201901710D0 (en) * | 2019-02-07 | 2019-03-27 | Nordic Bioscience As | Collagen type 23 assay |
| CN110467663B (zh) * | 2019-06-18 | 2022-05-10 | 华南农业大学 | Rspo3基因在母猪卵巢颗粒细胞中的应用 |
| EP4012021A4 (en) * | 2019-08-05 | 2022-11-30 | Genex Health Co.,Ltd | METHOD FOR CULTIVATION OF PRIMARY CELLS OF SOLID TUMORS IN LUNG CANCER AND PRIMARY TUMOR CELLS OF PLEEURAL EFFORT IN LUNG CANCER AND SUPPORTING REAGENT |
| KR20220082007A (ko) | 2019-10-08 | 2022-06-16 | 넥틴 테라퓨틱스 리미티드 | 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도 |
| US20230338466A1 (en) * | 2020-06-03 | 2023-10-26 | Children's Hospital Medical Center | Compositions and methods comprising r-spondins for treatment of tumors |
| CN112457400B (zh) * | 2020-12-09 | 2022-03-08 | 福州迈新生物技术开发有限公司 | 抗β-catenin蛋白单克隆抗体、细胞系及其制备方法和应用 |
| WO2023147470A2 (en) | 2022-01-28 | 2023-08-03 | Georgiamune Inc. | Antibodies to programmed cell death protein 1 that are pd-1 agonists |
| CN116239680B (zh) * | 2023-02-09 | 2024-02-06 | 义翘神州(泰州)科技有限公司 | 猴痘病毒a29小鼠单克隆包被抗体及检测抗体 |
| KR102551095B1 (ko) * | 2023-03-21 | 2023-07-04 | 순천향대학교 산학협력단 | 신규한 항-인간 알스폰딘2 항체 및 이의 용도 |
| KR102554222B1 (ko) * | 2023-03-21 | 2023-07-11 | 순천향대학교 산학협력단 | 신규한 항-인간 알스폰딘3 항체 및 이의 용도 |
| CN118546941A (zh) * | 2024-07-29 | 2024-08-27 | 上海奥浦迈生物科技股份有限公司 | 一种rspo1蛋白的表达载体及其应用 |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US20070124581A1 (en) | 1992-05-17 | 2007-05-31 | Reena Khare | Cell adhesion and extracellular matrix proteins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6828422B1 (en) | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| CA2288343A1 (en) | 1997-04-25 | 1998-11-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| EP1017811A4 (en) | 1997-09-24 | 2002-08-14 | Merck & Co Inc | HG38 GLYCOPROTEIN HORMONE RECEPTOR COUPLED WITH G-PROTEIN |
| US20020065394A1 (en) | 1998-03-18 | 2002-05-30 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
| WO1999048921A1 (en) | 1998-03-26 | 1999-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Novel mammalian g-protein coupled receptors having extracellular leucine rich repeat regions |
| US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
| US20030166047A1 (en) | 1999-05-06 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | Lgr6 nucleic acids and uses thereof |
| ATE482275T1 (de) | 1999-07-02 | 2010-10-15 | Morphosys Ag | Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden |
| CA2378403A1 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
| AU2001234944A1 (en) | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US6824973B2 (en) | 2000-02-03 | 2004-11-30 | Kirin Beer Kabushiki Kaisha | Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide |
| DE60129799T2 (de) | 2000-03-31 | 2008-04-30 | The General Hospital Corp., Boston | Verfahren zur steigerung des haarwuchses durch wnt polypeptid |
| JP2003530124A (ja) | 2000-04-05 | 2003-10-14 | 麒麟麦酒株式会社 | 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質 |
| EP1156062A1 (en) | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| WO2001092297A2 (en) | 2000-05-30 | 2001-12-06 | Bayer Aktiengesellschaft | Regulation of human lgr4-like g protein-coupled receptor |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| US20050089518A1 (en) | 2001-12-07 | 2005-04-28 | Clarke Michael F. | Prospective identification and characterization of breast cancer stem cells |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US6768004B2 (en) | 2001-01-11 | 2004-07-27 | Mueller Sybille | Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies |
| US20040077048A1 (en) | 2002-01-30 | 2004-04-22 | Warren Bridget A. | Protein modification and maintenance molecules |
| US7411052B2 (en) | 2001-03-05 | 2008-08-12 | Nuvelo, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US20100292155A1 (en) | 2001-03-05 | 2010-11-18 | Arca Biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US20030032034A1 (en) | 2001-03-05 | 2003-02-13 | Tang Y. Tom | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US7320880B2 (en) | 2001-06-11 | 2008-01-22 | Nuvelo, Inc. | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and DNA coding for the same |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20030022217A1 (en) | 2001-07-02 | 2003-01-30 | Pe Corporation (Ny) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| EP1427747B1 (en) | 2001-08-30 | 2012-04-11 | ARCA biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US20050130145A1 (en) | 2001-10-03 | 2005-06-16 | Henry Yue | Secreted proteins |
| US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
| US20040197778A1 (en) | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
| WO2003054152A2 (en) | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| EP1499637A1 (en) | 2002-04-26 | 2005-01-26 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same |
| EP1380644A1 (en) | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004074436A2 (en) | 2003-02-19 | 2004-09-02 | Incyte Corporation | Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer |
| US20050003405A1 (en) | 2003-04-30 | 2005-01-06 | Hua-Chien Chen | Treatment and diagnostics of cancer |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005110009A2 (en) | 2003-07-22 | 2005-11-24 | Immunex Corporation | COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d |
| DE10339820A1 (de) | 2003-08-22 | 2005-03-17 | Hinzmann, Bernd, Dr. | Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| ATE466106T1 (de) * | 2003-10-10 | 2010-05-15 | Deutsches Krebsforsch | Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen |
| WO2005040828A2 (en) | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49) |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| SG149059A1 (en) | 2004-01-27 | 2009-01-29 | Nuvelo Inc | Gastrointestinal proliferative factor and uses thereof |
| AU2005209909B8 (en) | 2004-02-03 | 2009-01-15 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| EP1725585A2 (en) | 2004-03-10 | 2006-11-29 | Lonza Ltd | Method for producing antibodies |
| US20080312425A1 (en) | 2004-08-30 | 2008-12-18 | Lonza Biologics Plc. | Ion Exchange Chromatography and Purification of Antibodies |
| WO2006031825A2 (en) | 2004-09-13 | 2006-03-23 | Macrogenics, Inc. | Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof |
| CA2591665C (en) | 2004-12-20 | 2015-05-05 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
| US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
| CA2604844A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics, Inc. | Cancer-related genes |
| EP1917022A2 (en) | 2005-07-26 | 2008-05-07 | Kirin Pharma Kabushiki Kaisha | Anti-tumor agents comprising r-spondins |
| US7541431B2 (en) | 2005-09-07 | 2009-06-02 | Maine Medical Center | Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto |
| EP1942926A4 (en) | 2005-10-07 | 2010-06-16 | Nuvelo Inc | STEM CELL FACTOR ARTIFICIAL PROTEIN SCFA1 AND ITS USES |
| EP1945754B1 (en) | 2005-10-31 | 2014-07-23 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| MX2008015138A (es) | 2006-06-02 | 2009-01-28 | Aveo Pharmaceuticals Inc | Proteinas de union al factor de crecimiento de hepatocitos (fch). |
| US7649083B2 (en) | 2006-06-02 | 2010-01-19 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding antibody |
| US7919092B2 (en) | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
| ZA200900545B (en) | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
| JP2008044926A (ja) | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Ｗｎｔ信号伝達に関係した分泌タンパク質 |
| AR062709A1 (es) | 2006-09-08 | 2008-11-26 | Genentech Inc | Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt |
| HRP20160082T1 (hr) | 2006-09-29 | 2016-02-26 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka |
| HUE027179T2 (en) | 2006-10-20 | 2016-10-28 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Angiogenesis and vasculogenesis modulator for Rspond |
| WO2008075796A1 (ja) | 2006-12-21 | 2008-06-26 | Kyowa Hakko Kirin Co., Ltd. | 血球回復促進剤 |
| WO2008088524A2 (en) | 2006-12-28 | 2008-07-24 | Nuvelo, Inc. | Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| CN101842389A (zh) | 2007-06-12 | 2010-09-22 | 惠氏有限责任公司 | 抗cd20治疗组合物和方法 |
| ES2694018T3 (es) | 2007-07-02 | 2018-12-17 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para el tratamiento y el diagnóstico del cáncer |
| US20120082659A1 (en) | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| EP2188630A4 (en) | 2007-10-02 | 2010-11-03 | Univ Rochester | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC ANSWERS TO ONCOGENIC MUTATIONS |
| CN104109208A (zh) | 2007-11-14 | 2014-10-22 | 中外制药株式会社 | 使用抗gpr49抗体的癌症的诊断和治疗 |
| US8093364B2 (en) | 2008-01-18 | 2012-01-10 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| WO2010002862A2 (en) | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| WO2010016766A2 (en) | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Antibodies recognizing endogenous human lgr5 and/or lgr6 |
| EP2331136B1 (en) | 2008-09-26 | 2018-01-10 | OncoMed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| CN102245767B (zh) | 2008-10-31 | 2013-09-18 | 东丽株式会社 | 人cxcl1蛋白质的免疫学测定方法 |
| US20120039912A1 (en) | 2009-04-15 | 2012-02-16 | Galapagos Sasu | Rspondin-3 inhibition in bone disorders |
| WO2010129284A1 (en) | 2009-04-27 | 2010-11-11 | The Trustees Of The University Of Pennsylvania | Inhibition of hair follicle growth by the wnt inhibitor dkk1 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| MX2011013722A (es) | 2009-06-18 | 2012-05-08 | Wyeth Llc | Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. |
| WO2011009090A1 (en) | 2009-07-16 | 2011-01-20 | Xoma Technology Ltd. | Antibodies to high molecular weight melanoma associated antigen |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| ES2573643T3 (es) | 2009-12-23 | 2016-06-09 | Deutsches Krebsforschungszentrum | Receptores de Rspo2 y Rspo3 |
| US8663950B2 (en) | 2010-01-11 | 2014-03-04 | Arizona Board Of Regents | Production of a monoclonal antibody therapeutic against west nile virus in plants |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| EP2523974A4 (en) | 2010-01-12 | 2013-11-06 | Oncomed Pharm Inc | WNT BINDER AND APPLICATIONS THEREOF |
| KR20120117931A (ko) | 2010-02-12 | 2012-10-24 | 온코메드 파마슈티칼스, 인크. | 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법 |
| AU2011352167A1 (en) | 2010-12-28 | 2013-07-11 | Caris Mpi, Inc. | Molecular profiling for cancer |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| WO2012148003A1 (en) | 2011-04-28 | 2012-11-01 | Sbi Biotech Co., Ltd. | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
| WO2013012747A1 (en) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| ES2769786T3 (es) | 2011-10-14 | 2020-06-29 | Recordati Ag | Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt |
| EP2773664A1 (en) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
| ES2697674T3 (es) | 2011-11-01 | 2019-01-25 | Bionomics Inc | Procedimientos para bloquear el crecimiento de células madre cancerosas |
| BR112014019741A2 (pt) | 2012-02-11 | 2020-12-22 | Genentech, Inc | Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| CN104854132A (zh) | 2012-07-13 | 2015-08-19 | 昂考梅德药品有限公司 | Rspo3结合剂及其用途 |
| JP2016518328A (ja) | 2013-03-12 | 2016-06-23 | キュアジェニックス インコーポレイテッド | 癌治療のための化合物 |
| US20160116478A1 (en) | 2013-05-30 | 2016-04-28 | Order-Made Medical Research Inc. | Reagent including anti-lgr6 antibodies for detection and diagnosis of cancer |
| US20150147333A1 (en) | 2013-10-18 | 2015-05-28 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
| US9777052B2 (en) | 2014-12-02 | 2017-10-03 | The Board Of Regents Of The University Of Oklahoma | R-spondin variants, compositions, and methods of use |
| MA41123A (fr) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
-
2012
- 2012-07-13 WO PCT/US2012/046746 patent/WO2013012747A1/en not_active Ceased
- 2012-07-13 CN CN201280045135.9A patent/CN104023746B/zh not_active Expired - Fee Related
- 2012-07-13 EP EP12814264.3A patent/EP2731625B1/en active Active
- 2012-07-13 CA CA2841745A patent/CA2841745A1/en not_active Abandoned
- 2012-07-13 BR BR112014000765A patent/BR112014000765A2/pt unknown
- 2012-07-13 RU RU2014101669/10A patent/RU2014101669A/ru not_active Application Discontinuation
- 2012-07-13 US US13/549,050 patent/US8802097B2/en not_active Expired - Fee Related
- 2012-07-13 CN CN201610353524.8A patent/CN106167526A/zh active Pending
- 2012-07-13 MX MX2014000555A patent/MX349198B/es active IP Right Grant
- 2012-07-13 JP JP2014520383A patent/JP6185463B2/ja not_active Expired - Fee Related
- 2012-07-13 AU AU2012284254A patent/AU2012284254B2/en not_active Ceased
- 2012-07-13 KR KR1020147003901A patent/KR20140048276A/ko not_active Ceased
- 2012-07-13 EP EP18162940.3A patent/EP3401329A1/en not_active Withdrawn
-
2014
- 2014-01-13 IL IL230429A patent/IL230429A0/en unknown
- 2014-01-15 CL CL2014000114A patent/CL2014000114A1/es unknown
- 2014-01-22 ZA ZA2014/00525A patent/ZA201400525B/en unknown
- 2014-06-27 US US14/318,247 patent/US9109024B2/en not_active Expired - Fee Related
- 2014-06-27 US US14/318,253 patent/US9109025B2/en not_active Expired - Fee Related
-
2015
- 2015-07-09 US US14/795,811 patent/US9644034B2/en not_active Expired - Fee Related
-
2017
- 2017-04-05 US US15/480,081 patent/US20170298143A1/en not_active Abandoned
- 2017-05-11 JP JP2017094648A patent/JP2017169578A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529641A5 (enExample) | ||
| ES3055227T3 (en) | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) | |
| CN106573977B (zh) | 针对ceacam1的人源化抗体 | |
| JP2022071038A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達を破壊することによる癌免疫療法 | |
| JP7368856B2 (ja) | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 | |
| JP2022068352A (ja) | 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体の組合せを用いる肺癌の処置法 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| ES2877757T3 (es) | Tratamiento terapéutico de cáncer de mama basado en el estado de c-MAF | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2020529863A (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| KR20160024391A (ko) | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2013512278A5 (enExample) | ||
| JP2019517498A (ja) | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体 | |
| EP2702408A1 (en) | Methods of treating squamous cell carcinoma related applications | |
| CN110088137A (zh) | 针对mica和micb蛋白的抗体 | |
| TW201642897A (zh) | Ｈｅｒ２結合劑治療 | |
| JP2019520034A5 (enExample) | ||
| US20210246219A1 (en) | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof | |
| JP2021503911A (ja) | 抗ｏｘ４０抗体及びその用途 | |
| CN118871467A (zh) | 抗pd-l2抗体 | |
| JP2025509183A (ja) | がんの処置のためのｋｒａｓ阻害剤を含む併用療法 | |
| JP2021502344A (ja) | 腫瘍を処置する方法 | |
| JP2022529969A (ja) | 固形腫瘍を治療する薬物の調製における抗ｐｄ－１抗体の応用 | |
| KR20220100099A (ko) | 위암의 검출 및 치료를 위한 조성물 및 방법 |